CN111050776A - 用于抑制hmgb1表达的组合物和方法 - Google Patents

用于抑制hmgb1表达的组合物和方法 Download PDF

Info

Publication number
CN111050776A
CN111050776A CN201880056295.0A CN201880056295A CN111050776A CN 111050776 A CN111050776 A CN 111050776A CN 201880056295 A CN201880056295 A CN 201880056295A CN 111050776 A CN111050776 A CN 111050776A
Authority
CN
China
Prior art keywords
oligonucleotide
nucleotides
seq
sequence
hmgb1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880056295.0A
Other languages
English (en)
Chinese (zh)
Inventor
M.阿布拉姆斯
G.乔达
朴智慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of CN111050776A publication Critical patent/CN111050776A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880056295.0A 2017-06-29 2018-06-29 用于抑制hmgb1表达的组合物和方法 Pending CN111050776A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762526971P 2017-06-29 2017-06-29
US62/526971 2017-06-29
PCT/US2018/040410 WO2019006375A1 (en) 2017-06-29 2018-06-29 COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION

Publications (1)

Publication Number Publication Date
CN111050776A true CN111050776A (zh) 2020-04-21

Family

ID=64735107

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880056295.0A Pending CN111050776A (zh) 2017-06-29 2018-06-29 用于抑制hmgb1表达的组合物和方法

Country Status (10)

Country Link
US (2) US10675295B2 (enExample)
EP (1) EP3645013A4 (enExample)
JP (1) JP2020529197A (enExample)
KR (1) KR20200023427A (enExample)
CN (1) CN111050776A (enExample)
AU (1) AU2018294415A1 (enExample)
CA (1) CA3068630A1 (enExample)
IL (2) IL271680B (enExample)
MX (1) MX2020000154A (enExample)
WO (1) WO2019006375A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454221A (zh) * 2018-12-12 2021-09-28 迪克纳制药公司 含有三元环的双链核酸抑制剂分子
WO2024061202A1 (zh) * 2022-09-20 2024-03-28 北京福元医药股份有限公司 用于抑制hmgb1基因表达的双链核糖核酸及其修饰物、缀合物和用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675295B2 (en) 2017-06-29 2020-06-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting HMGB1 expression
CN111971051A (zh) * 2018-04-13 2020-11-20 迪克纳制药公司 用增加tm的核苷酸修饰的双链核酸抑制剂分子
IL284327B2 (en) * 2018-12-28 2024-11-01 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting hmgb1 expression
KR20230171431A (ko) * 2021-04-14 2023-12-20 다이서나 파마수이티컬, 인크. Pnpla3 발현을 조절하기 위한 조성물 및 방법
IL307154A (en) * 2021-04-19 2023-11-01 Novo Nordisk As Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
CN117280031A (zh) * 2021-04-19 2023-12-22 诺和诺德股份有限公司 用于抑制核受体亚家族1组h成员3（nr1h3）表达的组合物和方法
KR20240046843A (ko) * 2021-08-25 2024-04-11 노보 노르디스크 에이/에스 알파-1 항트립신 발현을 억제하기 위한 조성물 및 방법
JP7877458B2 (ja) * 2021-12-01 2026-06-22 ディセルナ ファーマシューティカルズ インコーポレイテッド Ａｐｏｃ３発現を調節するための組成物及び方法
TWI868755B (zh) * 2022-06-24 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106244589A (zh) * 2016-08-01 2016-12-21 中国人民解放军第四军医大学 靶向hmgb1基因的rna干扰片段及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
US20110081362A1 (en) * 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
WO2010033225A2 (en) * 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
WO2011007876A1 (ja) * 2009-07-16 2011-01-20 Ｎｅｃソフト株式会社 Ｈｍｇｂ１結合核酸分子およびその用途
EP2617426B1 (en) * 2010-09-17 2016-08-10 Japan Science and Technology Agency Inhibitor of hmgb protein-mediated immune response activation
WO2014028494A1 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Detecting and treating liver damage
US10351854B2 (en) * 2014-10-10 2019-07-16 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
EP3865576A1 (en) * 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
WO2017079227A1 (en) * 2015-11-05 2017-05-11 University Of Connecticut Compositions and methods for the treatment of liver fibrosis
US10675295B2 (en) 2017-06-29 2020-06-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting HMGB1 expression
WO2019126097A1 (en) * 2017-12-18 2019-06-27 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
US11883019B2 (en) 2017-12-21 2024-01-30 Cilag Gmbh International Stapling instrument comprising a staple feeding system
IL284327B2 (en) 2018-12-28 2024-11-01 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting hmgb1 expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106244589A (zh) * 2016-08-01 2016-12-21 中国人民解放军第四军医大学 靶向hmgb1基因的rna干扰片段及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
QUAN GONG等: "High-mobility group box 1 exacerbates concanavalin A-induced hepatic injury in mice", 《JOURNAL OF MOLECULAR MEDICINE》 *
RUOCHAN CHEN等: "Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases", 《MOLECULE MEDICINE》 *
TRACY S. ZIMMERMANN等: "Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate", 《MOLECULAR THERAPY》 *
WENJING ZENG等: "Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease", 《SCIENTIFIC REPORTS》 *
WEN-SONG GE等: "Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells", 《WORLD JOURNAL OF GASTROENTEROLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454221A (zh) * 2018-12-12 2021-09-28 迪克纳制药公司 含有三元环的双链核酸抑制剂分子
WO2024061202A1 (zh) * 2022-09-20 2024-03-28 北京福元医药股份有限公司 用于抑制hmgb1基因表达的双链核糖核酸及其修饰物、缀合物和用途

Also Published As

Publication number Publication date
US10675295B2 (en) 2020-06-09
EP3645013A4 (en) 2021-07-21
IL295086A (en) 2022-09-01
JP2020529197A (ja) 2020-10-08
US20190000870A1 (en) 2019-01-03
KR20200023427A (ko) 2020-03-04
AU2018294415A1 (en) 2020-01-16
US11478501B2 (en) 2022-10-25
IL271680B (en) 2022-09-01
IL271680A (en) 2020-02-27
US20200297754A1 (en) 2020-09-24
WO2019006375A1 (en) 2019-01-03
MX2020000154A (es) 2020-07-22
EP3645013A1 (en) 2020-05-06
CA3068630A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
US11478501B2 (en) Compositions and methods for inhibiting HMGB1 expression
JP7357002B2 (ja) 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド
CN111601891A (zh) 用于抑制aldh2表达的组合物和方法
JP7453921B2 (ja) Ｇｙｓ２発現を阻害するための組成物及び方法
JP2024516356A (ja) ケトヘキソキナーゼ（ｋｈｋ）を阻害するための組成物及び方法
US20220072024A1 (en) Compositions and methods for inhibiting hmgb1 expression
CN119403927A (zh) 用于抑制跨膜丝氨酸蛋白酶6（tmprss6）表达的组合物和方法
TW202330920A (zh) 用於調節ａｐｏｃ３表現之組合物及方法
US20220186229A1 (en) Methods and compositions for inhibiting expression of cyp27a1
HK40028777A (en) Compositions and methods for inhibiting hmgb1 expression
TW202345873A (zh) 調節ｓｃａｐ活性之組合物及方法
CN117280031A (zh) 用于抑制核受体亚家族1组h成员3（nr1h3）表达的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40028777

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200421